Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression

BACKGROUND: Use of unboosted atazanavir (ATV(400)) is approved in the US but not in Europe [1]. Due to pharmacokinetic interactions it should not be used with tenofovir but can be used with abacavir/lamivudine (ABC/3TC) [1, 2,3]. Effectiveness data of ATV(400)+ABC/3TC as a switch strategy in clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Llibre, Josep M, Cozzi-Lepri, Alessandro, Antonio Valencia La Rosa, Jorge, Pedersen, Court, Ristola, Matti, Losso, Marcelo, Mocroft, Amanda, Mitsura, Victor M., Ormaasen, Vidar, Maltez, Fernando, Beniowski, Marek, Paredes, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P278
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225315/
https://www.ncbi.nlm.nih.gov/pubmed/25397554
http://dx.doi.org/10.7448/IAS.17.4.19810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225315/
https://www.ncbi.nlm.nih.gov/pubmed/25397554
http://dx.doi.org/10.7448/IAS.17.4.19810

Ejemplares similares